NeuroTherapia is a clinical-stage, privately held biotechnology company developing oral, small-molecule drugs to address neuro-inflammatory conditions of the central nervous system (CNS), including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and other CNS conditions. The company is focused on therapeutics that inhibit microglia cells, which drive inflammation in the CNS, without affecting the clearance of toxic beta amyloid.
Market
Neuro-inflammatory conditions of the central nervous system
Location
Gates Hill,
Ohio,
USA
Coinvestors
Alzheimer's Drug Discovery Foundation, Brain Trust Accelerator Fund, Cleveland Clinic, CRUINT, Dolby Family Ventures, Foundation for a Better World